BDTX
vs
S&P 500
BDTX
S&P 500
Over the past 12 months, BDTX has underperformed S&P 500, delivering a return of +2% compared to the S&P 500's +14% growth.
Stocks Performance
BDTX vs S&P 500
Performance Gap
BDTX vs S&P 500
Performance By Year
BDTX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Black Diamond Therapeutics Inc
Glance View
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 88 full-time employees. The company went IPO on 2020-01-30. The firm is focused on the discovery and development of small molecule, MasterKey therapies. The Company’s technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Its lead product candidate, BDTX-189, is designed as an orally available, irreversible small molecule inhibitor that targets a spectrum of 48 non-canonical and canonical driver mutations of the ErbB kinases epidermal growth factor receptor (EGFR) and HER2. BDTX-1535 is designed as a brain-penetrant small molecule inhibitor that targets a spectrum of EGFR mutations, including allosteric and canonical mutations. The company also has early-stage programs, such as B-Raf Proto-Oncogene (BRAF), and fibroblast growth factor receptor (FGFR).
